The Clinical study of Yiqi Jiedu compound combined with Pembrolizumab in the treatment of non-small cell lung cancer patients with chemotherapy resistance

ongHua Hospital, Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Those who met the diagnostic criteria of primary bronchogenic carcinoma and were diagnosed as lung squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and large cell carcinoma by pathology or cytology;
•(2) After conventional platinum chemotherapy, according to RECIST 1.1, the patient suffered from radiologic disease progression determined by the researcher;
•(3) After EGFR/ALT-TKIs treatment, according to RECIST 1.1, the patient had the progression of radiologic disease as determined by the investigator;
•(4) TCM syndrome differentiation belongs to Qi and yin deficiency, lung and kidney essence deficiency, phlegm and toxin accumulation type;
•(5) Aged >= 18 years;
•(6) The expected survival time was more than 3 months;
•(7) Blood routine test, liver and kidney function, electrocardiogram were basically in the normal range;
•(8) Volunteer to participate in clinical research and sign informed consent.

•(1) Patients receiving concurrent radiotherapy, chemotherapy and targeted therapy;
•(2) They have been treated with anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs.
•(3) Patients with interstitial pneumonia and poor lung function;
•(4) People with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and psoriasis;
•(5) Those who have undergone organ and hematopoietic stem cell transplantation;
•(6) Pregnant or lactating patients;
•(7) Patients with mental history.

发起方

ongHua Hospital, Shanghai University of Traditional Chinese Medicine